Mayo Clinic Gastrointestinal Cancers 2019: Current and Emerging Strategies in Multidisciplinary Care is organized by Mayo Clinic and will be held from Mar 14 - 16, 2019 at Hyatt Regency La Jolla at Aventine, San Diego, California, United States of America.
The target audience for this medical event is Medical Oncologists, Radiation Oncologists, Surgical Oncologists, GI Surgeons, Gastroenterologists and Hepatologists involved in cancer care, Interventional Radiologists, Pharmacists, Nurse Practitioners, Physician Assistants, and Nurses and any healthcare professional involved in the care of GI malignancies. This CME Conference has been approved for a maximum of 14.50 AMA PRA Category 1 Credits.
This course will focus on case-based and didactic presentations from Mayo Clinic and other international experts in the treatment of the whole spectrum of gastrointestinal (GI) cancers including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal, and gallbladder.
The primary goal of this course is to guide practicing physicians on integrating the best and most current evidence into their day-to-day routine care for patients with GI cancers. This course will also bring a practical perspective on how to optimize multidisciplinary care for some of the more complex clinical management decisions. Topics discussed will include: locoregional modalities, the role of minimally invasive procedures and state-of-the-art radiation modalities.
Upon conclusion of this program, participants should be able to:
• Interpret the most up-to-date and practice-relevant data presented at various cancer-related meetings in 2018.
• Integrate evidence-based interdisciplinary treatment strategies into clinical practice in various fields of medical oncology.
• Determine the usefulness of biomarker-based treatment approaches in oncology.
• Determine the current and future role of immunotherapy strategies in various GI malignancies.
• Select the appropriate treatment strategy for patients with early stage cancers of GE junction, rectum, pancreas, and liver.
• Identify ideal patients with hepatobiliary cancers and neuroendocrine tumors that would be candidates for transplant.
• Describe the molecular biology and genetics of colorectal cancers.
• Integrate statistical knowledge into the interpretation of published and presented data.
• Select the appropriate regimens for sequencing therapies across multiple GI malignancies.
Additional details will be posted as soon as they are available.
|Registration Type||End Date||Price|
|Physician, Scientist Early Fee||11 Jan,2019||USD 650.00|
|Physician, Scientist Late Fee||13 Mar,2019||USD 725.00|
|Resident, Fellow, NP, PA Early Fee||11 Jan,2019||USD 550.00|
|Resident, Fellow, NP, PA Late Fee||13 Mar,2019||USD 625.00|
|Allied Health Professional, Retiree Early Fee||11 Jan,2019||USD 550.00|
|Allied Health Professional, Retiree Late Fee||13 Mar,2019||USD 625.00|